A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market

A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market

The New York Times - Business:

Leaders of the treatment’s manufacturer, Amylyx, said they would announce their plans for it within eight weeks.

This post first appeared in The New York Times - Business. Read the original article.